MarketPulse

blockbuster drugs

2 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Beyond Weight Loss: Eli Lilly's Diversified Pipeline Offers More Growth Than Rivals

Eli Lilly's oncology and immunology portfolios rival its blockbuster weight-loss drugs, positioning the company better than Novo Nordisk for long-term growth.
LLYNVOCNTAgene therapyweight loss drugs
The Motley FoolThe Motley Fool··Adria Cimino

Vertex Pharmaceuticals Diversifies Beyond Cystic Fibrosis With Gene-Editing Expansion

Vertex Pharmaceuticals expands beyond cystic fibrosis dominance into gene-editing treatments for blood disorders and pain management, targeting $13.1B revenue with non-CF products generating $500M+.
VRTXbiotechpharmaceutical innovation